[Home ] [Archive]   [ فارسی ]  
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
:: Volume 19, Issue 6 (Iranian South Medical Journal 2017) ::
Iran South Med J 2017, 19(6): 951-961 Back to browse issues page
Nano Packaged Diblock and Curcumin: a New Approach Inorder To Drug Resistance in Breast Cancer
Samira Hajigholami1, Ziba Vaise Malekshahi 2
1- Genetic group, School of biological sciences, Tarbiat Modares University Tehran, Iran
2- Medical Biotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran , zvmalekshahi@yahoo.com
Abstract:   (4541 Views)

Background: Breast cancer is one of the causes of mortality in the world. Half of patients with metastatic extend resistance to Tamoxifen and almost all patients eventually become resistant to tamoxifen. Inorder to counteract with the negative effects of tamoxifen, this drug have been placed in combination with the curcumin. Anti-cancer substance which is less toxic than Tamoxifen. In this study, Diblock (Dendrosome) Nano polymer was used in order to tamoxifen packaging along with curcumin. Anti-cancer efficacy of the obtained compound (Diblock, Tamoxifen and Curcumin) was evaluated in Tamoxifen-resistant (TR)
MCF-7 cells and Fibroblast cells.

Material and Methods: MTT Assay was used to evaluate anti-proliferation effect and drug toxicity.Flow cytometry and Annexin-V-FLUOS were used inorder to assay anti-proliferation effect and induction of apoptosis, respectively.

Results: Nano-compound has less toxicity effects on normal cells compared with Tamoxifen and increased apoptosis activity and decreased proliferation in MCF-7 cells which are resistant to tamoxifen. Curcumin and Tamoxifen have more apoptotic potential than Tamoxifen alone, Nano-Tamoxifen or Nano-Curcumin.

Conclusion: Results of this study showed that changes in Tamoxifen by curcumin polymeric nanocarrier help to more effective treatment of breast cancer.

Keywords: Curcumin, Tamoxifen, Polymer Nano-carrier, Breast Cancer
Full-Text [PDF 953 kb]   (1259 Downloads)    
Subject: Pharmacology
Received: 2016/12/27 | Accepted: 2016/12/27 | Published: 2016/12/27
1. Fisch T, Pury P, Probst N, et al. Variation in survival after diagnosis of breast cancer in Switzerland. Ann Oncol 2005; 16(12): 1882-8. [PubMed] [Google Scholar]
2. Bray F, McCarron P, Parkin DM. The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Res 2004; 6(6): 229-39. [PubMed] [Google Scholar]
3. Farooq S, Coleman MP. Breast cancer survival in South Asian Women in England and Wales. J Epidemiol Community Health 2005; 59(5): 402-6. [PubMed] [Google Scholar]
4. Reeder JG, Vogel VG. Breast cancer prevention. Cancer Treat Res 2008; 141: 149-64. [PubMed] [Google Scholar]
5. Petinari L, Kohn L, de Carvalho JE, et al. Cytotoxicity of tamoxifen in normal and tumoral cell lines and its ability to induce cellular transformation in vitro. Cell Bio Int 2004; 28(7): 531-9. [PubMed] [Google Scholar]
6. Chen HY, Yang YM, Han R, et al. MEK1/2 inhibition suppresses tamoxifen toxicity on CNS glial progenitor cells. J Neurosci 2013; 33(38): 15069-74. [PubMed] [Google Scholar]
7. De Gasperi M, Cavazos D. Curcumin Modulates Tamoxifen Response in Resistant Breast Cancer Cells. Cancer Res 2009; 69(24): 3098. [Google Scholar]
8. Ireson CR, Jones DJ, Orr S, et al. Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine. Cancer Epidemiol Biomarkers Prev 2002; 11(1): 105-11. [PubMed] [Google Scholar]
9. Moorthi C, Kathiresan K. Curcumin–Piperine/Curcumin Quercetin/Curcumin–Silibinin dual drug-loaded nanoparticulate combination therapy: A novel approach to target and treat multidrug-resistant cancers. J Med Hypo Ideas 2013; 7(1): 15-20. [Google Scholar]
10. Hatcher H, Planalp R, Cho J, et al. Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci 2008; 65(11): 1631-52. [PubMed] [Google Scholar]
11. Grynkiewicz G, Slifirski P. Curcumin and curcuminoids in quest for medicinal status. Acta Biochim Pol 2012; 59(2): 201-12. [PubMed] [Google Scholar]
12. Babaei E, Sadeghizadeh M, Hassan ZM, et al. Dendrosomal curcumin significantly suppresses cancer cell proliferation in vitro and in vivo. Int Immunopharmacol 2012; 12(1): 226-34. [PubMed] [Google Scholar]
13. Jimeno A, Hidalgo M. Multitargeted therapy: can promiscuity be praised in an era of political correctness. Crit Rev Oncol Hematol 2006; 59(2): 150-8. [PubMed] [Google Scholar]
14. Kunnumakkara AB, Anand P, Aggarwal BB. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancer through interaction with multiple cell signaling proteins. Cancer Lett 2008; 269(2): 199-225. [PubMed] [Google Scholar]
15. Jiang M, Huang O, Zhang X, et al. Curcumin induces cell death and restores tamoxifen sensitivity in the antiestrogen-resistant breast cancer cell lines MCF-7/LCC2 and MCF-7/LCC9. Molecules 2013; 18(1): 701-20. [PubMed] [Google Scholar]
16. Nass N, Brömme HJ, Hartig R, et al. Differential response to α-oxoaldehydes in tamoxifen resistant MCF-7 breast cancer cells. PloS One 2014; 9(7): e101473. [PubMed] [Google Scholar]
17. Chaudhary LR, Hruska KA. Inhibition of cell survival signal protein kinase B/Akt byc urcumin in human prostate cancer cells. J Cell Biochem 2003; 89(1): 1-5. [PubMed] [Google Scholar]
18. Bush JA, Cheung KJ Jr, Li G. Curcumin induces apoptosis in human melanoma cells through a Fas receptor/caspase-8 pathway independent of p53. Exp Cell Res 2001; 271(2): 305-14. [PubMed] [Google Scholar]
Send email to the article author

Add your comments about this article
Your username or Email:


XML   Persian Abstract   Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Hajigholami S, Vaise Malekshahi Z. Nano Packaged Diblock and Curcumin: a New Approach Inorder To Drug Resistance in Breast Cancer. Iran South Med J. 2017; 19 (6) :951-961
URL: http://ismj.bpums.ac.ir/article-1-843-en.html

Volume 19, Issue 6 (Iranian South Medical Journal 2017) Back to browse issues page
دانشگاه علوم پزشکی بوشهر، طب جنوب ISMJ

Iranian South Medical Journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License which allows users to read,
copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly

Copyright © 2017, Iranian South Medical Journal| All Rights Reserved

Persian site map - English site map - Created in 0.08 seconds with 31 queries by YEKTAWEB 4137